MedTrace Logo

Allogeneic SCT of CordIn™, in Patients With Hemoglobinopathies

NCT02504619 · Status: TERMINATED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 1

Last updated 2019-06-26

Study results available
· View outcomes & findings →

Summary

CordIn™ is a cryopreserved stem/progenitor cell-based product of purified CD133+ cells composed of ex vivo expanded allogeneic UCB cells. The overall study objectives are to evaluate the safety and efficacy of CordIn™.

Conditions

Interventions

BIOLOGICAL

CordIn

CordIn™ is a cryopreserved stem/progenitor cell-based product of purified CD133+ cells composed of ex vivo expanded allogeneic UCB cells.

Sponsors & Collaborators

  • Gamida Cell ltd

    lead INDUSTRY

Principal Investigators

  • Jean-Hugues Dalle, MD · Robert Debre, Paris, France

  • Franco Locatelli, MD · IRCCS Ospedale Pediatrico Bambino Gesu, Rome, Italy

  • Allistair Abraham, MD · Children's National, Washington DC

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
2 Years
Max Age
25 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-04-04
Primary Completion
2016-08-31
Completion
2017-12-31

Countries

  • United States
  • France

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02504619 on ClinicalTrials.gov